DocuSign Inc (DOCU) concluded trading on Thursday at a closing price of $74.70, with 6.52 million shares of worth about $487.04 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 36.91% during that period and on March 13, 2025 the price saw a loss of about -6.78%. Currently the company’s common shares owned by public are about 202.00M shares, out of which, 199.77M shares are available for trading.
Stock saw a price change of -6.36% in past 5 days and over the past one month there was a price change of -15.04%. Year-to-date (YTD), DOCU shares are showing a performance of -16.94% which increased to 28.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $48.70 but also hit the highest price of $107.86 during that period. The average intraday trading volume for DocuSign Inc shares is 2.40 million. The stock is currently trading -9.46% below its 20-day simple moving average (SMA20), while that difference is down -15.28% for SMA50 and it goes to 5.23% higher than SMA200.
DocuSign Inc (NASDAQ: DOCU) currently have 202.00M outstanding shares and institutions hold larger chunk of about 88.61% of that.
The stock has a current market capitalization of $15.09B and its 3Y-monthly beta is at 1.21. PE ratio of stock for trailing 12 months is 15.39, while it has posted earnings per share of $4.85 in the same period. It has Quick Ratio of 0.83 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DOCU, volatility over the week remained 5.17% while standing at 3.92% over the month.
Stock’s fiscal year EPS is expected to rise by 3.96% while it is estimated to increase by 10.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on March 10, 2025 offering a Neutral rating for the stock and assigned a target price range of between $70 and $75 to it. On April 12, 2024, UBS Upgrade their recommendations, while on January 16, 2024, Morgan Stanley Upgrade their ratings for the stock with a price target of $64. Stock get an Underweight rating from Wells Fargo on December 20, 2023.
